成人先天性心脏病右室-肺动脉管道置入的长期结局:基于国家死亡指数的生存分析
该回顾性研究纳入1991至2017年232例接受右室-肺动脉管道置入的成人先天性心脏病患者,比较肺动脉同种瓣与Medtronic Freestyle猪瓣的长期结局。随访中位9.1年,两组再干预免除率无显著差异,但Freestyle组跨瓣压差更高;先天性肺动脉狭窄和法洛四联症患者生存优于其他诊断患者。
要点
- 肺动脉同种瓣与Freestyle猪瓣再干预免除率无显著差异。
- Freestyle猪瓣跨瓣压差高于肺动脉同种瓣。
- 先天性肺动脉狭窄和法洛四联症患者生存优于其他诊断患者。
核心结论
- 两种瓣膜在再手术免除率方面表现相当,但Freestyle患者跨瓣压差更高。
- 先天性肺动脉狭窄和法洛四联症患者生存优于其他原发诊断患者。
研究设计与样本
- 回顾性病历审查,纳入1991至2017年连续接受右室-肺动脉管道置入的成人先天性心脏病患者。
- 共232例患者,中位年龄31.5岁(四分位距25-41岁),其中肺动脉同种瓣84例、Freestyle猪瓣148例。
- 通过澳大利亚国家死亡指数获取死亡原因和日期以计算生存函数。
主要发现
- 总体中位随访时间9.1年(四分位距5.3-12.6年)。
- 平均跨瓣压差肺动脉同种瓣组为11.8 ± 7.1 mmHg,Freestyle猪瓣组为16.6 ± 9.6 mmHg。
- 先天性肺动脉狭窄患者20年生存率100%;法洛四联症患者5、10、15、20年生存率分别为99%、97%、96%、96%。
- 其他原发诊断患者5、10、15、20年生存率分别为93%、91%、87%、87%。
- 再干预免除率在5年和10年时肺动脉同种瓣组为98.6%、98.6%,Freestyle猪瓣组为97.5%、93%,两组无显著差异。
临床怎么用
- 对于成人先天性心脏病需右室-肺动脉管道置入者,两种瓣膜再干预风险相当,选择时可综合考虑跨瓣压差表现。
- 先天性肺动脉狭窄和法洛四联症患者长期生存较好,其他诊断患者需更密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to investigate the long-term outcomes following right ventricle-to-pulmonary artery (RV-to-PA) conduit insertion of Medtronic Freestyle® porcine valve (MFV) or pulmonary allograft valve (PAV) in adult patients with congenital heart disease. METHODS: Retrospective medical record review of consecutive RV-to-PA conduit insertion, using either PAV or MFV from 1991 to 2017. Perioperative data and clinic reports were collected. Cause and date of death were obtained from the Australian National Death Index to obtain survival function. RESULTS: In total, 232 patients (median age 31.5 years, interquartile range 25-41 years) underwent RV-to-PA conduit insertion (PAV = 84 and MFV = 148) and were eligible for inclusion [63.8% tetralogy of Fallot (TOF); 11.6% congenital pulmonary stenosis (PS); 24.6% other diagnoses]. The overall median follow-up time was 9.1 years (interquartile range 5.3-12.6 years). The mean gradient was 11.8 ± 7.1 mmHg in PAV and 16.6 ± 9.6 mmHg in MFV patients. Congenital PS patients had 100% survival at 20 years, TOF patients at 5, 10, 15 and 20 years had 99%, 97%, 96% and 96% survival, respectively. Patients with other primary diagnoses at 5, 10, 15 and 20 years had 93%, 91%, 87% and 87% respectively. Freedom from reintervention did not differ significantly at 5 and 10 years between pulmonary allograft (98.6%, 98.6%) and Freestyle® porcine bioprosthesis (97.5%, 93%). CONCLUSIONS: Both valves perform equally well with regard to patients' freedom from reoperation, although transvalvular gradient was higher for Freestyle® patients. Congenital PS and TOF patients had better survival than patients with other primary diagnoses.
引用
- Thuraisingam A, Skillington P, Ludhani P, et al. Long-term outcomes of right ventricle-to-pulmonary artery conduit insertion in adults with congenital heart disease: survival analysis by National Death Index. Eur J Cardiothorac Surg. 2021. PMID: 33779724. doi:10.1093/ejcts/ezab148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。